Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Mcrae Capital Management Inc.

Mcrae Capital Management Inc. boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 7.2% in the fourth quarter, HoldingsChannel.com reports. The fund owned 35,558 shares of the pharmaceutical company’s stock after buying an additional 2,399 shares during the quarter. Vertex Pharmaceuticals comprises about 3.3% of Mcrae Capital Management Inc.’s investment portfolio, making the stock its 13th biggest holding. Mcrae Capital Management Inc.’s holdings in Vertex Pharmaceuticals were worth $16,121,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in Vertex Pharmaceuticals by 1.0% during the third quarter. Vanguard Group Inc. now owns 24,216,865 shares of the pharmaceutical company’s stock worth $9,484,293,000 after acquiring an additional 243,088 shares during the last quarter. Capital Research Global Investors raised its position in Vertex Pharmaceuticals by 2.8% during the third quarter. Capital Research Global Investors now owns 16,553,281 shares of the pharmaceutical company’s stock worth $6,482,978,000 after acquiring an additional 444,990 shares during the last quarter. Capital International Investors raised its position in Vertex Pharmaceuticals by 77.9% during the third quarter. Capital International Investors now owns 4,689,059 shares of the pharmaceutical company’s stock worth $1,836,550,000 after acquiring an additional 2,053,156 shares during the last quarter. Alliancebernstein L.P. raised its position in Vertex Pharmaceuticals by 3.3% during the third quarter. Alliancebernstein L.P. now owns 4,522,586 shares of the pharmaceutical company’s stock worth $1,771,226,000 after acquiring an additional 144,266 shares during the last quarter. Finally, Norges Bank acquired a new position in Vertex Pharmaceuticals during the fourth quarter worth about $1,440,149,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Buying and Selling

In related news, CMO Carmen Bozic sold 6,988 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $450.00, for a total transaction of $3,144,600.00. Following the completion of the transaction, the chief marketing officer owned 26,088 shares of the company’s stock, valued at approximately $11,739,600. This represents a 21.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Joy Liu sold 1,104 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $425.02, for a total transaction of $469,222.08. Following the transaction, the executive vice president directly owned 20,729 shares of the company’s stock, valued at $8,810,239.58. This trade represents a 5.06% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 11,717 shares of company stock valued at $5,309,945. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Price Performance

NASDAQ:VRTX opened at $428.34 on Thursday. The firm has a 50 day simple moving average of $437.63 and a 200-day simple moving average of $451.81. The firm has a market cap of $108.71 billion, a PE ratio of 25.41, a P/E/G ratio of 1.82 and a beta of 0.30. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $507.92.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 EPS for the quarter, topping the consensus estimate of $4.24 by $0.23. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. The firm had revenue of $2.99 billion during the quarter, compared to analyst estimates of $2.99 billion. During the same quarter in the prior year, the business posted $4.06 earnings per share. Vertex Pharmaceuticals’s revenue for the quarter was up 8.3% compared to the same quarter last year. As a group, sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 16.99 earnings per share for the current fiscal year.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: The FDA accepted Vertex’s Biologics License Application for povetacicept in adults with IgA nephropathy, putting the company one step closer to a potential new nephrology launch and a regulatory decision expected on November 30, 2026. This is an important pipeline milestone that could expand Vertex’s growth story beyond cystic fibrosis. FDA Accepts Vertex’s BLA for Povetacicept in IgA Nephropathy
• Positive Sentiment: Vertex will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, with CEO Reshma Kewalramani scheduled for a fireside chat. Investors may view the event as an opportunity for management to discuss pipeline updates and long-term strategy. Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10
• Neutral Sentiment: Recent commentary suggests VRTX has been trading modestly above its last earnings level, with analysts debating whether the stock can keep advancing after its latest results. This is more of a valuation/expectations check than a direct catalyst. Vertex (VRTX) Up 0.2% Since Last Earnings Report: Can It Continue?
• Neutral Sentiment: Other articles highlighted that Vertex has recently underperformed the broader healthcare sector and that its shares have consolidated after a strong multi-year run. These pieces reflect investor debate around current valuation rather than a specific fundamental setback. Vertex Pharmaceuticals Stock: Is VRTX Underperforming the Healthcare Sector?

Wall Street Analysts Forecast Growth

VRTX has been the subject of a number of research reports. Bank of America lifted their target price on shares of Vertex Pharmaceuticals from $571.00 to $598.00 and gave the stock a “buy” rating in a research report on Tuesday, March 10th. Barclays boosted their price objective on shares of Vertex Pharmaceuticals from $607.00 to $615.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Maxim Group raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $575.00 price objective for the company in a research report on Wednesday, March 18th. Citigroup boosted their price objective on shares of Vertex Pharmaceuticals from $575.00 to $585.00 and gave the company a “buy” rating in a research report on Tuesday, March 10th. Finally, Jefferies Financial Group started coverage on shares of Vertex Pharmaceuticals in a research report on Tuesday, March 10th. They issued a “buy” rating and a $580.00 price objective for the company. Twenty-two research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $555.91.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.